CK2 Inhibitors – New CK2 Kinase Inhibitors for antineoplastic drugs and diagnostics
Beside cardiovascular diseases, malignant tumours take
the second place in cause of human death. Neoplastic diseases are indicated by a high cell proliferation. The inhibition of this cell proliferation by an active agent in a medicament is a worldwide accepted approach for tumour therapy. Protein kinase CK2 belongs together with others to the group of second-messenger independent kinases. Despite of unambiguous references for the involvement of CK2 in malignant transformation, tumour origin and progression, there are only a few effective inhibitors for this enzyme on-hand. This invention provides access to a novel class of potent human CK2 kinase inhibitors. The disclosed compounds can be used as active ingredients e.g. for the treatment of neoplastic diseases. Further, the patent application discloses synthesis of the compounds with optimised product yield.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Parallel Paths: Understanding Malaria Resistance in Chimpanzees and Humans
The closest relatives of humans adapt genetically to habitats and infections Survival of the Fittest: Genetic Adaptations Uncovered in Chimpanzees Görlitz, 10.01.2025. Chimpanzees have genetic adaptations that help them survive…
You are What You Eat—Stanford Study Links Fiber to Anti-Cancer Gene Modulation
The Fiber Gap: A Growing Concern in American Diets Fiber is well known to be an important part of a healthy diet, yet less than 10% of Americans eat the minimum recommended…
Trust Your Gut—RNA-Protein Discovery for Better Immunity
HIRI researchers uncover control mechanisms of polysaccharide utilization in Bacteroides thetaiotaomicron. Researchers at the Helmholtz Institute for RNA-based Infection Research (HIRI) and the Julius-Maximilians-Universität (JMU) in Würzburg have identified a…